α1受体阻滞剂和5-磷酸二酯酶抑制剂联合治疗男性下尿路症状合并勃起功能障碍的临床研究

Study on the Combination of α1-receptor Blocker and PDE-5i in Treating LUTS and ED

目的：研究对下尿路症状（lower urinary tract symptom,LUTS）合并勃起功能障碍（erectile dysfunction,ED）的男性患者,α1受体阻滞剂和5-磷酸二酯酶抑制剂（Phosphodiesterase Type 5 inhibitor,PDE-5i）联合治疗相比于单药治疗的优势及安全性。方法：2012年1~5月我院门诊年龄〉50岁、主诉LUTS合并ED的患者共35名。随机分为三组,坦索罗辛单药治疗组（n=12）、西地那非单药治疗组（n=11）、坦索罗辛和西地那非联合治疗组（n=12）,共治疗12周。统计分析治疗前后国际前列腺症状评分（IPSS）和国际勃起功能评分（IIEF）有无改善。结果：坦索罗辛组、西地那非组、联合治疗组的IPSS和IIEF分别改善了50.3%和11.2%、10.1%和49.7%、61.2%和58.9%。三组治疗前后的IPSS和IIEF均有显著改善（P〈0.05）。其中,联合治疗组的IPSS和IIEF改善最明显。结论：对于LUTS合并ED的部分患者,α1受体阻滞剂和PDE-5抑制剂的联合治疗优于单药治疗。

Objective：To investigate the advantages and safety of the combination of α1-receptor blocker and PDE-5i in treating LUTS and ED compared with monotherapy.Methods：Thirty-five cases aged 50 years or above who complained LUTS and ED were included.They were randomly divided into three groups： tamsulosin（n=12）,sildenafil（n=11） and combination of both（n=12）,and treated for 12 weeks.The IPSS and IIEF scores were analyzed.Results： Improvement of the IPSS and IIEF scores in all groups was significant（P0.05）.The improvement of the IPSS and IIEF scores in the combination group（61.2% and 58.9%,respectively） was greatest and there was significant difference compared with the tamsulosin group（50.3% and 11.2% respectively） or the sildenafil group（10.1% and 49.7% respectively）.Conclusion：The combination of α1-receptor blocker and PDE-5i was superior to monotherapy in treating LUTS and ED.